Two oral presentations and multiple posters on clinical andpreclinical-stage candidates to be presented at SITC, demonstratingthe strength of Immatics’ TCR-T PRAME franchise to target solid cancers ACTengine® IMA203 demonstrates 54% cORR, 12.1 months mDOR and 6 months mPFS in heavily pretreated metastatic melanoma patients and >1-year mPFS in patients with deep responses; Company plans to start its randomized-controlled Phase 3 SUPRAME trial in December 2024 to evaluate IMA203 in second-line or later metas ...

Data continues positive trend as additional patients are enrolled in 3 cohorts Vaccine was safe and well tolerated by participants in all 3 cohorts Protocol defined immune responses were exhibited in over 70% of patients A Phase 2 study evaluating the vaccine in the neoadjuvant setting is planned to commence in 2025SAN JOSE, Calif., Nov. 8, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ...

New data showed a correlation between the levels of neural cell adhesion molecule (NCAM or CD56) expression and response and disease control in patients treated with CTX-471 monotherapy.Predictive biomarkers correlated with response and changes in pharmacodynamic markers were seen in patients treated with CTX-471, a novel anti-CD137 agonist antibody, in an analysis from the Phase 1 monotherapy study. BOSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncol ...

Core Insights - Medicenna Therapeutics Corp. announced promising preclinical data for its novel immunotherapy MDNA113, which targets IL-13Rα2 and shows potential for treating a wide range of malignancies, including "cold tumors" affecting over two million patients annually [1][6] - The company will present updated clinical results from the MDNA11 Phase 1/2 ABILITY-1 study at the 39th Annual Meeting of SITC [1][2] Group 1: MDNA113 Overview - MDNA113 is a novel IL-13Rα2 tumor-targeted BiSKIT designed to deliver an anti-PD1-IL-2 Superkine to the tumor microenvironment, activated by tumor-associated proteases [1][6] - Treatment with MDNA113 resulted in complete tumor regression in IL-13Rα2 expressing tumors, indicating its effectiveness in aggressive cancer models [2][3] - The drug demonstrated the ability to prevent metastasis in a triple-negative breast cancer model when administered prior to surgery, achieving 100% survival [3][4] Group 2: Preclinical and Clinical Data - Preclinical studies showed that MDNA113 significantly inhibited tumor growth in IL-13Rα2 positive tumors and improved tolerability compared to unmasked anti-PD1-IL-2SK [3][4] - Independent research indicated that MDNA11 and anti-PD1-IL-2SK BiSKIT extended overall survival in aggressive glioblastoma mouse models and stimulated immune cell activity in human GBM explants [2][4] - Ex-vivo studies with patient-derived GBM explants treated with IL-2SK or anti-PD1-IL-2SK showed increased CD8+ T and NK cell populations alongside reduced tumor burden [5] Group 3: Medicenna's Technology Platforms - MDNA113 is based on Medicenna's IL-2 and IL-13 Superkine platforms, with MDNA11 being a long-acting IL-2 super agonist currently in clinical evaluation [2][7] - MDNA11 is engineered to preferentially activate immune effector cells while minimizing stimulation of immunosuppressive Tregs, enhancing its therapeutic potential [7][8] - Medicenna focuses on developing highly selective versions of Superkines to address unmet needs in oncology, with ongoing studies for various cancer types [8]

HONG KONG, Nov. 7, 2024 /PRNewswire/ -- At the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024), held in Houston, USA, from November 6 - 10, Akeso Biopharma (9926. HK) presented the mechanism of action (MOA) research findings of its innovative bispecific antibody, AK132, targeting both Claudin18.2 (CLDN18.2) and CD47. AK132 is an asymmetric bispecific antibody with a "1+1" valency, designed to simultaneously target and block CLDN18.2 and CD47. It features a wild-type IgG1 Fc struct ...

Less frequent IV dosing with nemvaleukin in patients with select advanced solid tumors, including ovarian cancer and mucosal melanoma, showed tumor site-specific pharmacodynamic activity and immune activation Preclinical data demonstrated durable immune responses and tumor growth inhibition with Mural’s IL-18 variants, reinforcing pursuit of IND-enabling studies with candidate nomination anticipated by the end of 2024, and IND submission expected in Q4 2025 Additional preclinical data from Mural’s IL-12 pro ...

Preliminary data demonstrate durable and dose-dependent T cell responses targeting KRAS mutations and induced responses to patient-specific neoantigens Correlation observed between disease-free survival (“DFS”) and T cell response ELI-002 Phase 1 safety and tolerability profile remains favorable ELI-002 Phase 2 interim event-driven DFS analysis expected in H1 2025 BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechn ...

Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)Presenting new clinical data from Phio's on-going Phase 1b trialNovember 07, 2024 10:00 AM EST | Source: Phio Pharmaceuticals Corp.Marlborough, Massachusetts--(Newsfile Corp. - November 7, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company creating new pathways towards a cancer-free future by using its INTASYL® siRNA gene sile ...

- Interim phase 1 clinical trial update reveals the clinical potential of the tumor-activated IL-12 prodrug WTX-330, with favorable tolerability profile and encouraging efficacy signals - - Additional preclinical data demonstrate INDUKINETM molecules’ anti-tumor potency with distinct immune activation profiles across four cytokines - WATERTOWN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) --  Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneerin ...

NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announces compelling safety, pharmacokinetics, and biomarker data on its lead compound, Decoy20, at the Society for Immunotherapy of Cancer (SITC) 2024 annual meeting. The data derive from two cohorts (13 patients) of Decoy20 single administration and one cohort (6 patients) of De ...